ESMO Congress

AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.

In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.

Inavolisib demonstrated a favorable safety profile and generated disease control in patients with tumors harboring PIK3CA mutations.

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.

Lutetium Lu 177 dotatate shows consistent efficacy over high-dose octreotide in advanced GEP-NETs, according to data from the NETTER-2 trial.

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

Neoadjuvant TAR-200 plus cetrelimab elicited responses and was safe in muscle-invasive bladder cancer.

Taletrectinib elicited high and durable overall response rates with favorable tolerability in patients with advanced ROS1-positive NSCLC.

NIAGARA was the first phase 3 study to evaluate perioperative immunotherapy plus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

Perioperative nivolumab extended event-free survival vs placebo in patients with resectable non–small cell lung cancer.

Early switch therapy to atezolizumab after run-in with vemurafenib plus cobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive melanoma.

RP1 plus nivolumab offers durable responses and a favorable safety profile for patients with melanoma after progression on anti–PD-1 therapy.

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Pembrolizumab continued to demonstrate improved survival vs ipilimumab in unresectable stage III or IV melanoma.

The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.

Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.

The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.